RxDoctor Payments Data

Natalia Palacio, MD

Internal Medicine · Dallas, TXNPI 1396999819

Payments from drug & device makers

$1,275in general payments, 2019–2025

Across 69 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$178
  • GSK$146
  • Johnson & Johnson$144
  • Lilly USA, LLC$134
  • Pfizer$119
  • Novo Nordisk$91
  • plus $463 from 13 others

What the payments were for

  • Food & beverage$1,275100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,275 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$81,276
Medicare patients
172
Services billed
746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide31$33,174
OzempicSemaglutide33$31,999
JardianceEmpagliflozin22$30,859
FarxigaDapagliflozin Propanediol11$18,777
JanuviaSitagliptin Phosphate11$15,626
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,765
Aspirin-Dipyridamole ErAspirin/Dipyridamole12$4,990
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$3,861
Dexlansoprazole DrDexlansoprazole13$3,030
Atorvastatin Calcium313$2,690
Rosuvastatin Calcium185$2,127
Levothyroxine Sodium181$1,998
Amlodipine Besylate232$1,579
Ezetimibe51$1,452
Famotidine85$1,450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$134$33,17431 claims
Novo NordiskOzempic$91$31,99933 claims
Boehringer IngelheimJardiance$68$30,85922 claims
AstraZenecaFarxiga$43$18,77711 claims
MerckJanuvia$17$15,62611 claims
GSKTrelegy Ellipta$146$7,76512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →